School of Medicine
Showing 501-520 of 1,603 Results
-
Rachel Gilgoff
Adjunct Clinical Associate Professor, Pediatrics - Allergy and Clinical Immunology
BioAs a board-certified general pediatrician, child abuse pediatrician, and integrative medicine specialist, Dr. Gilgoff brings a multidisciplinary, whole-family approach to ACEs, toxic stress, healing, and well-being. She is currently an advisor with the California Aces Aware Initiative, UCLA-UCSF ACEs Aware Family Resilience Network (UCAAN), and the Center for Youth Wellness, a program of Safe and Sound, as well as an Adjunct Clinical Associate Professor at Stanford University School of Medicine. She is the co-founder of the National Committee on Asthma and Toxic Stress and co-PI on “Systems-based, Multidisciplinary Assessment of Adversity and Toxic Stress for Individualized Care (The SYSTEMAATIC Project),” an ACEs and Precision Medicine research project through the California Initiative to Advance Precision Medicine (CIAPM). She co-created the “Stress Busters: Clinical Strategies for Preventing and Mitigating Toxic Stress,” a free, on-line course to help clinicians develop their clinical response to childhood adversity and toxic stress. In tandem, she led the development of the ACEs Aware Stress Busters Resource Webpage, sharing tools and resources to prevent and heal toxic stress for all of us. Dr. Gilgoff is dedicated to conducting translational research and promoting patient-centered, individualized, multidisciplinary clinical care to address health issues resulting from child abuse and toxic stress.
Board Certification:
American Board of Physician Specialties, Integrative Medicine (2022)
American Board of Pediatrics, Child Abuse Pediatrics (2011)
American Board of Pediatrics, General Pediatrics (2004)
Professional Education
Fellowship:
Integrative Psychiatry Institute, Integrative Psychiatry (2023)
Andrew Weil Center for Integrative Medicine (2022)
Stanford University Medical Center, Pediatric Integrative Medicine (2021)
UCSF Benioff Children’s Hospital Oakland and UC Davis, Child Abuse Pediatrics (2007)
Residency:
UCSF Benioff Children’s Hospital and Research Center at Oakland (2004)
Medical Education:
Keck School of Medicine, USC (2001)
Selected Publications
Gilgoff R, Marshall J, Kotz K, Ismail S, Harsamizadeh Tehrani S,…; ACEs Aware Patient Advisors; ACEs Aware Community Partner Council. (2025) “Stress Busters Toolkit for Community Based Organizations: Strategies to help clients prevent and heal from toxic stress.” California ACEs Aware Initiative, Office of the California Surgeon General, and the California Department of Health Care Services. https://www.acesaware.org/managestress/cbotoolkit/
Gilgoff, R., Mengelkoch, S,, Elbers, J., Kotz, K., Radin, A., Pasumarthi, I., Murthy, R., Sindher, S., Burke Harris, N., Slavich, G.E. (2024) The Stress Phenotyping Framework: A Multidisciplinary Biobehavioral Approach for Assessing and Therapeutically Targeting Maladaptive Stress Physiology. Stress. 27 (1).
Gilgoff R, Schwartz T, Owen M, Bhushan D, Burke Harris N. (2023) Opportunities to Treat Toxic Stress. Pediatrics. Jan 1;151(1):e2021055591.
Jeung, J., Hessler Jones, D., Frame, L., Gilgoff, R., Long, D., Thakur, N., Koita, K., Bucci, M., Burke Harris, N. (2022) A Caregiver-Child Intervention for Mitigating Toxic Stress (“The Resiliency Clinic”): A Pilot Study. Matern Child Health J.
Bhushan D, Kotz K, McCall J, Wirtz S, Gilgoff R, Dube SR, Powers C, Olson-Morgan J, Galeste M, Patterson K, Harris L, Mills A, Bethell C, Burke Harris N. (2020) Office of the California Surgeon General. Roadmap for Resilience: The California Surgeon General’s Report on Adverse Childhood Experiences, Toxic Stress, and Health. Office of the California Surgeon General.
Gilgoff R, Singh L, Koita K, Gentile B, Marques SS. (2020) Adverse Childhood Experiences, Outcomes, and Interventions. Pediatr Clin North Am. Apr;67(2):259-273. -
Bertil Glader
Stanford Medicine Professor of Pediatric Hematology/Oncology, Emeritus
Current Research and Scholarly InterestsHematology/Oncology, biology, and treatment of bone marrow failure disorders, hereditary coagulation disorders-clinical trials.
-
Greg Glasscock
Clinical Associate Professor, Pediatrics - Neonatology
Current Research and Scholarly InterestsNeonatal Endocrinology
-
Anna L Gloyn
Professor of Pediatrics (Endocrinology) and of Genetics
Current Research and Scholarly InterestsAnna's current research projects are focused on the translation of genetic association signals for type 2 diabetes and glycaemic traits into cellular and molecular mechanisms for beta-cell dysfunction and diabetes. Her group uses a variety of complementary approaches, including human genetics, functional genomics, physiology and islet-biology to dissect out the molecular mechanisms driving disease pathogenesis.
-
Neville H. Golden M.D.
Marron and Mary Elizabeth Kendrick Professor of Pediatrics, Emeritus
Current Research and Scholarly InterestsMy research has focused on the medical complications of adolescents with eating disorders. My specific area of study has been the etiology and implications of amenorrhea in adolescents with eating disorders, in particular the management of reduced bone mass and osteoporosis in anorexia nervosa.
-
Natalia Gomez-Ospina
Assistant Professor of Pediatrics (Genetics)
Current Research and Scholarly Interests1. Genome Editing and HSPC-Based Therapeutics
Dr. Gomez-Ospina’s research focuses on developing autologous hematopoietic stem and progenitor cell therapies using CRISPR/Cas9-mediated genome editing. Her work includes targeted integration of therapeutic transgenes into genomic safe-harbor loci, optimization of editing efficiency and safety, and development of transplantation and conditioning strategies that preserve long-term engraftment. A major goal is to create reusable, mutation-agnostic therapeutic platforms that can be adapted across diseases. Her translational work also extends to GMP manufacturing, analytical development, and IND-enabling studies needed to move genome-edited HSPC products toward clinical trials.
2. Neurometabolic and Neurodegenerative Disease Therapeutics
A major area of interest is the development of definitive therapies for lysosomal storage disorders and other neurogenetic diseases, including MPS I, Gaucher disease, Krabbe disease, progranulin deficiency, and Friedreich’s ataxia. Her laboratory investigates how hematopoietic-derived cells can deliver therapeutic proteins to peripheral tissues and the central nervous system. This includes strategies to enhance microglial replacement, improve CNS engraftment, and harness myeloid cells as therapeutic vehicles. The broader objective is to establish cell-based approaches capable of treating both inherited neurometabolic disorders and more common neurodegenerative diseases.
3. Rare Disease Genetics, Functional Genomics, and Lysosome Biology
Dr. Gomez-Ospina also studies the molecular basis of rare and undiagnosed genetic disorders. Through clinical genetics, international collaborations, and the NIH Undiagnosed Diseases Network, her work contributes to novel disease-gene discovery, functional validation of candidate variants, and definition of genotype–phenotype relationships. Her laboratory also investigates lysosomal biology and develops systems-level approaches, including the Lysosome Disease Atlas, to connect lysosome-associated genes with cellular function and human phenotypes. These efforts aim to improve diagnosis while identifying new disease mechanisms and therapeutic opportunities.
For more information go to our website:
https://www.gomezospina.com/
